Aripiprazole in the Treatment of Irritability Associated with Autistic Disorder in Paediatric Patients†: Profile Report
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Only 2 medications have been formally approved for use with individuals with ASD and both of these medicines target irritability: risperidone (Risperdal, Janssen Pharmaceutical Inc.; Titusville, NJ) and aripiprazole (Abilify, Otsuka America Pharmaceutical Inc.; Rockville, MD) [27][28][29].”
From Treatment for Co-Occurring Attention Deficit/Hyperactivity Disorder and Autism Spectrum Disorder (2012) · cites this paper as [29]
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Aripiprazole in the Treatment of Irritability in Children and Adolescents With Autistic Disorder
Owen, R., Sikich, L., Marcus, R. N., Corey-Lisle, P., Manos, G., McQuade, R. D., Carson, W. H., & Findling, R. L. (2009) · Pediatrics · doi:10.1542/peds.2008-3782 · Cited by 613 · cited 10×
“multicenter, phase III trials that investigated the efficacy of aripiprazole (ARI) for the treatment of irritability associated with autistic disorder([15,16])”
BackgroundMethodInfluentialMarcus, R. N., Owen, R., Kamen, L., Manos, G., McQuade, R. D., Carson, W. H., & Aman, M. G. (2009) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e3181b76658 · Cited by 566 · cited 10×
“multicenter, phase III trials that investigated the efficacy of aripiprazole (ARI) for the treatment of irritability associated with autistic disorder([15,16])”
BackgroundMethodInfluentialFindling, R. L., Kauffman, R. E., Sallee, F. R., Salazar, D. E., Sahasrabudhe, V., Kollia, G. D., Kornhauser, D. M., Vachharajani, N. N., Assunção-Talbott, S., Mallikaarjun, S., et al. (2009) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2008.0111 · Cited by 54 · cited 7×
“07L/h/kg)([1]) and was consistent with that previously reported in adults.”
BackgroundResultInfluentialMalone, R. P., & Waheed, A. (2009) · Drugs · doi:10.2165/00003495-200969050-00003 · Cited by 53 · cited 1×
“While there are no approved treatments for the core symptoms of autistic disorder, various pharmacologic options have been investigated for treating the associated behavioural symptoms.([5]) Currently, the atypical antipsychotics risperidone([6]) and aripiprazole (Abilify )([7]) are approved by the US FDA for use in t…”
BackgroundRobb, A. S., Andersson, C., Bellocchio, E. E., Manos, G., Rojas-Fernandez, C., Mathew, S., Marcus, R., Owen, R., & Mankoski, R. (2011) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.10m01008gry · Cited by 35 · cited 8×
“001).([2,7]) Clinically significant weight gain (‡7% relative to baseline) was reported in 26% of aripiprazole recipients and 7% of placebo recipients.”
BackgroundMethodInfluentialCurran, M. P. (2011) · Pediatric Drugs · doi:10.2165/11207230-000000000-00000 · Cited by 18
Self-citation
Cited by
Treatment for Co-Occurring Attention Deficit/Hyperactivity Disorder and Autism Spectrum Disorder
Davis, N. O., & Kollins, S. H. (2012) · Neurotherapeutics · doi:10.1007/s13311-012-0126-9 · Cited by 156
“; Rockville, MD) [27–29].”
Iffland, M., Livingstone, N., Jorgensen, M. L., Hazell, P., & Gillies, D. M. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011769.pub2 · Cited by 71
Vohra, R., Madhavan, S., Sambamoorthi, U., StPeter, C., Poe, S. G., Dwibedi, N., & Ajmera, M. (2016) · Drugs - Real World Outcomes · doi:10.1007/s40801-016-0096-z · Cited by 62
“Most studies examining polypharmacy among individuals with ASD are limited to either pediatric populations and/or psychotropic polypharmacy [28, 31, 33, 34, 36, 38, 39, 40, 41] (with rates from 10 to 20%).”
BackgroundEspadas, C., Ballester, P., Londoño, A. C., Almenara, S., Aguilar, V., Belda, C., Pérez, E., & Peiró, A. M. (2020) · Psychiatry Research · doi:10.1016/j.psychres.2020.113321 · Cited by 33
Kirino, E. (2014) · Clinical Medicine Insights Pediatrics · doi:10.4137/cmped.s8304 · Cited by 31
Metadata
- Authors
- Curran, M. P.
- Affiliations
- Wolters Kluwer Health (NZ)
- Corresponding author
- Curran, Monique P.
- Venue
- CNS Drugs
- Published
- 2011-09
- Volume
- 25
- Issue
- 9
- Pages
- 801-802
- ISSN
- 1172-7047 (ISSN-L)
- OpenAlex
- W972969832
- Cited by
- 10
- References
- 7
- Citations by year
- 2023: 1 · 2020: 1 · 2018: 1 · 2017: 1 · 2016: 2 · 2014: 3 · 2012: 1
- FWCI
- 0.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- CNS Drugs (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Keywords
- aripiprazole, irritability, autistic disorder, autism spectrum disorder, pediatric patients, antipsychotic drugs
- MeSH terms
- Aripiprazole, Adolescent, Autistic Disorder, Child, Double-Blind Method, Humans, Irritable Mood, Piperazines, Quinolones, Randomized Controlled Trials as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Aripiprazole in the Treatment of Irritability Associated with Autistic Disorder in Paediatric Patients†: Profile Report. https://app.cochat.ai/papers/10.2165/11208280-000000000-00000
- The paper
- Curran, M. P. (2011). Aripiprazole in the Treatment of Irritability Associated with Autistic Disorder in Paediatric Patients†: Profile Report. CNS Drugs. https://doi.org/10.2165/11208280-000000000-00000
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.